Literature DB >> 27677697

Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia.

C Rueda1, M Puig-Asensio2, J Guinea3, B Almirante2, M Cuenca-Estrella1, O Zaragoza4.   

Abstract

OBJECTIVE: Paradoxical growth (PG) and trailing effect (TE) are frequently observed during antifungal susceptibility testing (AFST). These two phenomena interfere with the determination of the minimal inhibitory concentration (MIC). The aim of this study was to assess the clinical impact of TE and PG.
METHODS: We analysed the frequency of TE and PG of 690 Candida isolates collected from a population-based study performed in Spain (CANDIPOP) and correlated the results with clinical outcome of the patients.
RESULTS: Around 70% (484/690) of the isolates exhibited TE to azoles. Candida tropicalis showed the highest presence of TE (39/53 isolates exhibited residual growth >25% of control). No TE was seen in most of the isolates from the psilosis complex. PG was mainly associated with echinocandins. In patients treated with fluconazole within the first 48 hours after blood sampling (n = 221), the presence of TE to azoles tended to be associated with lower 30-day mortality (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.25-1.00) but not with clinical failure (OR 0.85, 95% CI 0.45-1.54). In the subgroup of 117 patients treated with echinocandins, the presence of PG was not associated with patient's response to antifungal treatment (OR for 30-day mortality 1.63, 95% CI 0.76-4.03; OR for clinical failure 1.17, 95% CI 0.53-2.70).
CONCLUSIONS: TE or PG are widely expressed among Candida spp., although they do not seem to influence clinical outcome.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Azoles; Candida; Echinocandins; Paradoxical growth; Trailing effect

Mesh:

Substances:

Year:  2016        PMID: 27677697     DOI: 10.1016/j.cmi.2016.09.016

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

1.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

3.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

4.  Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models.

Authors:  K M T Astvad; D Sanglard; E Delarze; R K Hare; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Candida albicans and Candida dubliniensis Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles.

Authors:  Rania Ayadi; Emilie Sitterlé; Christophe d'Enfert; Eric Dannaoui; Marie-Elisabeth Bougnoux
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

6.  Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs.

Authors:  Robert T Todd; Anna Selmecki
Journal:  Elife       Date:  2020-07-20       Impact factor: 8.140

7.  Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance.

Authors:  Ulrike Binder; Maria Aigner; Brigitte Risslegger; Caroline Hörtnagl; Cornelia Lass-Flörl; Michaela Lackner
Journal:  J Fungi (Basel)       Date:  2019-09-04

8.  In Vitro Antifungal and Antivirulence Activities of Biologically Synthesized Ethanolic Extract of Propolis-Loaded PLGA Nanoparticles against Candida albicans.

Authors:  Anupon Iadnut; Ketsaya Mamoon; Patcharin Thammasit; Sudjai Pawichai; Singkome Tima; Kanya Preechasuth; Thida Kaewkod; Yingmanee Tragoolpua; Khajornsak Tragoolpua
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-30       Impact factor: 2.629

9.  Adaptation of the emerging pathogenic yeast Candida auris to high caspofungin concentrations correlates with cell wall changes.

Authors:  Violeta Lara-Aguilar; Cristina Rueda; Irene García-Barbazán; Sarai Varona; Sara Monzón; Pilar Jiménez; Isabel Cuesta; Ángel Zaballos; Óscar Zaragoza
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 10.  Susceptibility Testing of Fungi to Antifungal Drugs.

Authors:  Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Fungi (Basel)       Date:  2018-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.